COVID-19 Worsens Neurological Problems, Delirium
At AD/PD 2021, clinicians discussed neurological symptoms and brain tissue damage in older people who died from COVID-19.
ALL NEWS
6510 RESULTS
Sort By:
- Most Recent
- Most Commented
For α-Synuclein Immunotherapy, Is Going Later the Key?
In the negative Phase 2 trial of prasinezumab, populations with more rapid decline benefited; this informed the design of a new Phase 2b study.
Field Loses David Allsop, First to Isolate Amyloid
Both shy and funny, Allsop was a pioneer of modern Alzheimer's research.
New Mouse Models Better Mimic Tauopathy, Alzheimer's
Two mouse models presented at AD/PD may hand scientists more translationally relevant tools to explore LOAD pathophysiology and treatment. The tricks: targeted replacement and knocking in multiple GWAS variants.
Clinicians from Developing Nations Discuss Dementia in Their Populations
As life expectancy increases in countries such as Nigeria, Brazil, China, and others, so does the number of people with dementia. How to provide modern care for them?
Where to Now, Phospho-Tau?
Researchers envision p-tau-based blood tests for Alzheimer’s disease within a few years, but maybe not a stand-alone test.
N-Terminal Tau Antibodies Fade, Mid-Domain Ones Push to the Fore
The field is shifting from targeting tau’s tips to its mid-region, especially where tau binds microtubules. Several new candidates are in the clinic; whether the strategy will work remains to be seen.
Shuttle Unloads More Gantenerumab Into the Brain
New data presented at the AD/PD conference offer the first evidence that a brain-shuttle strategy can work in people; the lecanemab and aducanumab antibody programs offer small updates.
Astroglial Markers Poised for Stardom?
A new PET tracer. Plasma glial fibrillary acidic protein. Two new, promising surrogates for astrogliosis are filling in the Alzheimer’s biomarker toolbox. Both reflect Aβ amyloid better than they do tau tangles.
FTD Trials: The Now and the Future
At this year’s ICFTD meeting, researchers reviewed the lay of the land of current and planned trials for FTD, with glimpses of how the newly formed FTD Prevention Initiative seeks to coordinate treatment and prevention trials in the future.
Cohorts Band Together to Get Global FTD Trials Going
The FTD Prevention Initiative merges cohort studies from across the world with a common goal—to execute effective clinical trials for FTD.
International Conference on Alzheimer's and Parkinson's Diseases 2021 (Virtual)
Donanemab Confirms: Clearing Plaques Slows Decline—By a Bit Astroglial Markers Poised for Stardom? Shuttle Unloads More Gantenerumab Into the Brain N-Terminal Tau Antibodies Fade, Mid-Domain Ones Push to the Fore Where to Now, Phospho-Tau? Clinicians from
Donanemab Confirms: Clearing Plaques Slows Decline—By a Bit
The Phase 2 trial provides the strongest evidence yet that removing most amyloid from the brain bolsters cognition, although the benefit is small.
From Specialized to Standardized: Social-Emotional Tests for FTD
Disturbed social and emotional cognition are among the most troubling features of FTD. They, too, can be quantified with new tools.
Moving Target: Can Standardized Tests Track Symptoms of FTD?
People with FTD wrestle with behavioral, cognitive, language, and motor impairments. Scientists are designing standardized tests that capture such symptoms.
Current Filters
- Date Range : All x